Fig. 1 · Structure

Documents & Downloads

BMS-863233 (XL-413)

Cat. No. A13677 CAS 1169562-71-3

CDK inhibitor

BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.

In Stock

Publications for BMS-863233 (XL-413)

2 publications citing this product

  1. Gijs Zonderland, .et al. , Mol Cell, 2022, Sep 15;82(18):3350-3365 PMID: 36049481
  2. Wang C, .et al. , Nature, 2019, Oct 2 PMID: 31578521

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

XL413 (BMS-863233) inhibits CDC7–DBF4 kinase. In an independent purified human DDK autophosphorylation assay, its IC50 was 22.7 nM; this assay endpoint should not be treated as a cellular treatment concentration. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Cdc7 3.4 nM
Pim1 42 nM
CK2 212 nM

Cellular Effect

Cell Line Activity Value Description Reference
Caco-2 ED50 < 3 mg/kg Inhibition of CDC7-mediated MCM2 phosphorylation at Ser40/41 in human Caco2 cells xenografted in po dosed athymic nude mouse by after 4 hrs Western blot analysis [PMID: 22560567]
Caco-2 IC50 140 nM Inhibition of CDC7 in human Caco2 cells assessed as inhibition of MCM2 phosphorylation at Ser53 after 4 hrs [PMID: 22560567]
Caco-2 IC50 2142 nM Antiproliferative activity against human Caco2 cells assessed as decrease in cell viability after 3 days by Cell Titer-Glo assay [PMID: 22560567]
Caco-2 IC50 2685 nM Antiproliferative activity against human Caco2 cells after 3 days by BrdU incorporation assay [PMID: 22560567]

BMS-863233 (XL-413) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of BMS-863233 (XL-413) from 2 published references. In vitro models include purified human CDC7 with DBF4 residues 341–674.

BMS-863233 (XL-413) In Vitro Studies

XL413 activity depends on the cellular model. In 72-hour viability assays, the reported IC50 was 1.1 µM in Colo-205 cells and 22.9 µM in HCC1954 cells. Most lines in the eight-line 5 µM panel showed limited response. [1]

At 10 µM for 4 days, XL413 increased senescence-associated β-galactosidase staining in the displayed TP53-mutant liver-cancer models, whereas the displayed TP53-wild-type and non-transformed comparators showed little staining. These qualitative results describe the tested models. [2]

Inhibition of purified human CDC7–DBF4 kinase

Biochemical assay · Purified human CDC7 with DBF4 residues 341–674 [1]

XL413 inhibited DDK autophosphorylation with a reported IC50 of 22.7 nM. PHA-767491 was an active comparator (18.6 nM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DDK autophosphorylation inhibitionIC50 22.7 nM (95% CI 18 to 28.6 nM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing inhibitor concentrations; Figure 4 includes a no-inhibitor reference and no-DDK control.
Exposure duration
5 min preincubation, followed by a 30 min kinase reaction at 30°C
Method
Radiometric DDK autophosphorylation assay; 20 ng DDK and 1.5 µM cold ATP plus radiolabelled ATP
Reported limits
Assay solvent is not specified in the adopted kinase-assay paragraph.
Methods and source locations

Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413

Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.

Figure 4A-C; Results s3b; Methods s2a, s2c and s2e

DDK autophosphorylation inhibition: Radiolabelled bands quantified by ImageJ; GraphPad Prism fit. Figure 4 caption: mean of four independent measurements ± SD on separate days. — Figure 4C; Results s3b; Methods s2e

Cell-dependent XL413 viability response

Cell-based study · HCC1954 and Colo-205 human cancer cells; eight-line fixed-concentration panel [1]

At 5 µM for 72 h, XL413 had substantial activity in Colo-205 but limited effects in the other seven lines in Figure 3A. Dose-response IC50 values differed markedly between HCC1954 and Colo-205.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP-based viability inhibition in HCC1954IC50 22.9 µM (95% CI 11.9 to 43.9 µM)[1]
ATP-based viability inhibition in Colo-205IC50 1.1 µM (95% CI 0.67 to 1.71 µM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM in Figure 3A; increasing concentrations in Figure 3B,D
Exposure duration
72 h after drug addition
Method
CellTiter-Glo ATP-based viable-cell readout relative to vehicle control
Vehicle
Vehicle control; DMSO is explicitly identified for the separate Figure 5 follow-up, but Figure 3 vehicle composition is not specified.
Reported limits
Exact dose-response series and vehicle percentage are not specified in the adopted caption/method paragraph. No values are estimated from curves.
Methods and source locations

Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413

Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.

Figure 3A, B and D; Results s3a; Methods s2a and s2f

ATP-based viability inhibition in HCC1954: 72 h CellTiter-Glo; caption: mean of at least three separate measurements ± SD, reproducible on separate days. — Figure 3B; Results s3a

ATP-based viability inhibition in Colo-205: 72 h CellTiter-Glo; caption: mean of at least three separate measurements ± SD, reproducible on separate days. — Figure 3D; Results s3a

Model-dependent senescence-associated staining

Cell-based study · TP53-mutant liver-cancer cells Hep3B, Huh7, MHCC97H and PLC/PRF/5; TP53-wild-type SK-Hep1 and Huh6; non-transformed BJ, TIG-3, RPE-1 and MCF-10A cells [2]

After XL413 treatment, SA-β-Gal staining increased in the displayed TP53-mutant liver-cancer models, with little staining in the displayed wild-type and non-transformed comparators. This is a qualitative senescence-associated endpoint, not proof that every TP53-mutant cancer responds.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Senescence-associated β-galactosidase stainingQualitative microscopy Increased staining in displayed TP53-mutant liver-cancer cells relative to controls; little staining in displayed wild-type and non-transformed comparators.[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
4 days
Method
SA-β-Gal staining with a commercial kit; representative microscopy
Vehicle
Figure 2b labels an untreated/control comparison; vehicle composition is not specified for this panel.
Reported limits
No numerical staining fraction is reported in the adopted panel/caption; none is inferred. Per-experiment supplier assignment and tested salt form are not given.
Methods and source locations

Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413

Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.

Figure 2b and caption; Methods: Compounds and antibodies; SA-β-Gal staining

Senescence-associated β-galactosidase staining: Figure 2b is representative of three independent biological experiments; no quantitative percentage extracted. — Figure 2b and caption

BMS-863233 (XL-413) In Vivo Studies

In a Myc-overexpressing, Trp53-deficient mouse liver-cancer model, median survival was 17 days with vehicle, 22.5 days with XL413, 20 days with AZD8055 and 33 days with the combination. XL413 was given at 100 mg/kg and AZD8055 at 20 mg/kg by oral gavage, 6 days/week. Interpretation is limited by reported combination-related adverse events and exclusion of early adverse-event animals from longitudinal analyses; the precise impact on the survival analysis is unclear. [2]

XL413 and AZD8055 in an immunocompetent liver-cancer model

Animal study · Female C57BL/6 mice, 6–8 weeks old at model induction, bearing Myc-overexpressing, Trp53-deficient somatic HCC [2]

Combination-treated mice had a longer reported median survival than either monotherapy or vehicle in this model. The methods report adverse events in 17% of combination-treated animals; the reporting summary states early therapy-related adverse-event animals were excluded from longitudinal analyses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Therapy-induced adverse events in XL413 + AZD8055 groupReported proportion 17%[2]

Conditions shared by the study groups

Frequency
6 days/week
Treatment course
Until symptomatic endpoint
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleVehicle and both monotherapies were concurrent comparison groups.Median survival 17 days; n=11[2]
XL413
100 mg/kg XL413
Vehicle and both monotherapies were concurrent comparison groups.Median survival 22.5 days; n=10[2]
AZD8055
20 mg/kg AZD8055
Vehicle and both monotherapies were concurrent comparison groups.Median survival 20 days; n=11[2]
XL413 + AZD8055
100 mg/kg XL413 + 20 mg/kg AZD8055
Vehicle and both monotherapies were concurrent comparison groups.Median survival 33 days; n=11[2]
Vehicle
Model: Female C57BL/6 mice, 6–8 weeks old at model induction, bearing Myc-overexpressing, Trp53-deficient somatic HCC
Reported limits: Vehicle formulation not specified. Early adverse-event exclusions apply to longitudinal analyses; arm-specific exclusion counts and survival-analysis impact remain unclear.
XL413
Model: Female C57BL/6 mice, 6–8 weeks old at model induction, bearing Myc-overexpressing, Trp53-deficient somatic HCC
Route: Oral gavage
Reported limits: Vehicle formulation not specified. Early adverse-event exclusions apply to longitudinal analyses; arm-specific exclusion counts and survival-analysis impact remain unclear.
AZD8055
Model: Female C57BL/6 mice, 6–8 weeks old at model induction, bearing Myc-overexpressing, Trp53-deficient somatic HCC
Route: Oral gavage
Reported limits: Vehicle formulation not specified. Early adverse-event exclusions apply to longitudinal analyses; arm-specific exclusion counts and survival-analysis impact remain unclear.
XL413 + AZD8055
Model: Female C57BL/6 mice, 6–8 weeks old at model induction, bearing Myc-overexpressing, Trp53-deficient somatic HCC
Route: Oral gavage
Reported limits: Vehicle formulation not specified. Early adverse-event exclusions apply to longitudinal analyses; arm-specific exclusion counts and survival-analysis impact remain unclear.
Methods and source locations

Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413

Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.

Figure 4d and caption; Methods: Immunocompetent HCC murine models; Reporting Summary: Data exclusions, Randomization, Blinding

Therapy-induced adverse events in XL413 + AZD8055 group: Methods report a group-level proportion without a denominator in this passage. The reporting summary describes exclusion of early therapy-related adverse-event animals from longitudinal analyses; do not infer a safety rate for all treated animals. — Methods: Immunocompetent HCC murine models, toxicity paragraph; Reporting Summary: Data exclusions

Vehicle · Figure 4d caption; Methods: Immunocompetent HCC murine models; Reporting Summary: Data exclusions

XL413 · Figure 4d caption; Methods: Immunocompetent HCC murine models; Reporting Summary: Data exclusions

AZD8055 · Figure 4d caption; Methods: Immunocompetent HCC murine models; Reporting Summary: Data exclusions

XL413 + AZD8055 · Figure 4d caption; Methods: Immunocompetent HCC murine models; Reporting Summary: Data exclusions

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1169562-71-3
Applications CDK inhibitor
Formula C14H13Cl2N3O2
Molecular Weight 326.18
Synonyms BMS-863233; XL-413
SMILES
C1C[C@H](NC1)C2=NC(=O)C3=C(N2)C4=C(O3)C=CC(=C4)Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Warmed: 43 mg/mL (131.82 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BMS-863233 (XL-413) Research References

  1. [1] Sasi NK, Tiwari K, Soon FF, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds PloS one (2014). PMID: 25412417 DOI: 10.1371/journal.pone.0113300 Source material
  2. [2] Wang C, Vegna S, Jin H, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer Nature (2019). PMID: 31578521 DOI: 10.1038/s41586-019-1607-3 Source material

Publications

2 publications citing this product

  1. Gijs Zonderland, .et al. , Mol Cell, 2022, Sep 15;82(18):3350-3365 PMID: 36049481
  2. Wang C, .et al. , Nature, 2019, Oct 2 PMID: 31578521

Added to your cart

View Cart Checkout
Loading...